
Revelation Biosciences Inc is a clinical-stage life sciences company focused on the development of immunologic-based therapies for the prevention and treatment of disease. It has several product candidates in development. REVTx-99, the lead therapeutic candidate, is an intranasal immunomodulator to ... Revelation Biosciences Inc is a clinical-stage life sciences company focused on the development of immunologic-based therapies for the prevention and treatment of disease. It has several product candidates in development. REVTx-99, the lead therapeutic candidate, is an intranasal immunomodulator to prevent or treat infections caused by various respiratory viruses such as SARS-CoV-2, including its variants, influenza A and B, parainfluenza, rhinovirus, and RSV. REVTx-99 is also being developed for other indications such as: allergic rhinitis and chronic nasal congestion. REVTx-200 is an intranasal immunomodulator adjunct to be used in combination with an intramuscular vaccination for more complete immunity. REVTx-200 is based on the same technology used in REVTx-99. Show more
Période | Variation | Variation % | Ouver. | Haut | Bas | Moyenne Vol. Quot. | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | -0.415 | -12.3328380386 | 3.365 | 3.47 | 2.36 | 477012 | 2.99783304 | CS |
4 | -1.44 | -32.8018223235 | 4.39 | 4.54 | 2.36 | 173429 | 3.19876106 | CS |
12 | -2.5636 | -46.4959373186 | 5.5136 | 20.16 | 2.36 | 2604506 | 9.57531322 | CS |
26 | -10.938 | -78.758640553 | 13.888 | 20.16 | 2.36 | 1712134 | 10.45106258 | CS |
52 | -34.97 | -92.220464135 | 37.92 | 60.8 | 2.36 | 1409120 | 19.61531924 | CS |
156 | -28557.05 | -99.9896708683 | 28560 | 48384 | 2.36 | 1292553 | 8119.83508918 | CS |
260 | -140781.05 | -99.9979045914 | 140784 | 163800 | 2.36 | 1359444 | 10667.0121343 | CS |
Les dernières valeurs consultées apparaîtront dans cette boîte, vous permettant de choisir facilement les titres vus auparavant.
Assistance: support@advfn.fr
En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales